I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma
I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma
复制标题
I-131 间碘苄胍治疗是嗜铬细胞瘤和副神经节瘤的重要治疗选择
DOI：
10.1055/a-1759-2050
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Kinuya S
中科院分区：
文献类型：
--
作者：
Zhang X; Wakabayashi H; Kayano D;Inaki A;Kinuya S
嗜铬细胞瘤和副神经节瘤是一种罕见的嗜铬细胞神经内分泌肿瘤。目前有几种方法可用于治疗PPGL患者。这些治疗方式包括手术，化疗，分子靶向治疗和radiopharmaceuticals.MethodsI-131 metiodobenzylguanidine（mIBG），一个经典的放射性药物，可以采取通过特定的受体和定位到许多，但不是全部，PPGL cells.ResultsMany studies have investigated efficacy and toxicity of I-131 mIBG therapy.这些研究报告的客观，激素和症状的反应，以及耐受toxicities in patients.ConclusionThis article reviews报道的经验，谁经历了I-131 mIBG治疗PPGL的功能和治疗的缺陷为重点的患者。
AimPheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours of chromaffin cells. Several modalities are currently available to treat patients with PPGL. These treatment modalities include surgery, chemotherapy, molecular targeted therapy and radiopharmaceuticals.MethodsI-131 metaiodobenzylguanidine (mIBG), a classic radiopharmaceutical, can be taken up through specific receptors and sited into many, but not all, PPGL cells.ResultsMany studies have investigated the efficacy and toxicity of I-131 mIBG therapy. These studies reported significant results in terms of objective, hormonal and symptomatic responses as well as tolerable toxicities in patients.ConclusionThis article reviews the reported experiences of patients who underwent I-131 mIBG therapy for PPGL with a focus on functions and deficiencies of the therapy.